539 results on '"Pierik, Marieke"'
Search Results
2. A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial
3. Refining physical exercise training studies in patients with inflammatory bowel disease: patient selection and assessment of physical fitness changes
4. Optimizing the Maastricht Work-Related Support intervention in clinical patient care: the value of integrating action research into intervention mapping
5. Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
6. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
7. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission
8. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial
9. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility
10. Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)
11. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study
12. SMART-IBD: Better Health Care from the Patient’s Perspective
13. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
14. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
15. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes.
16. Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
17. Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission
18. Predictive algorithm for thiopurine-induced hepatotoxicity in IBD patients
19. Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn’s Disease
20. Corticosteroid enhances epithelial barrier function in intestinal organoids derived from patients with Crohn’s disease
21. Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice : International Delphi Consensus Recommendations
22. Systematic review: Patient‐related, microbial, surgical, and histopathological risk factors for endoscopic post‐operative recurrence in patients with Crohn's disease.
23. The faecal scent of inflammatory bowel disease: Detection and monitoring based on volatile organic compound analysis
24. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease
25. Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease
26. Vulvar and vaginal neoplasia in women with inflammatory bowel disease
27. Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study
28. An Umbrella Review of the Effectiveness of Digital Technologies for the Management of Inflammatory Bowel Disease
29. Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn’s disease
30. The prevalence of nodular regenerative hyperplasia of the liver in long-term thiopurine-treated inflammatory bowel disease patients
31. Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis
32. Scoping review on health-related physical fitness in patients with inflammatory bowel disease: Assessment, interventions, and future directions
33. Volatile metabolites in breath strongly correlate with gut microbiome in CD patients
34. Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases
35. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease
36. Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases
37. Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations
38. Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI Trial
39. Early infliximab trough levels in paediatric IBD patients predict sustained remission.
40. Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors
41. Scoping review on health-related physical fitness in patients with inflammatory bowel disease:Assessment, interventions, and future directions
42. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes
43. Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission:The Randomized Controlled LADI Trial
44. Ferric Carboxymaltose Versus Ferrous Fumarate in Anemic Children with Inflammatory Bowel Disease:The POPEYE Randomized Controlled Clinical Trial
45. Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry
46. Modulation of Intestinal Epithelial Permeability by Plasma from Patients with Crohn’s Disease in a Three-dimensional Cell Culture Model
47. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study
48. Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)
49. Incidence of microscopic colitis in the Netherlands. A nationwide population-based study from 2000 to 2012
50. The Intake of Dicarbonyls and Advanced Glycation Endproducts as Part of the Habitual Diet Is Not Associated with Intestinal Inflammation in Inflammatory Bowel Disease and Irritable Bowel Syndrome Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.